With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Subscribe To Our Newsletter & Stay Updated
